camptothecin has been researched along with B-Cell Chronic Lymphocytic Leukemia in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bernardi, R; Bongiovanni, L; Coltella, N; Ghia, P; Magliulo, D; Ponzoni, M; Scarfò, L; Valsecchi, R | 1 |
| Bartlett, NL; Johnson, JL; Peterson, BA; Ratain, MJ; Wagner-Johnston, N | 1 |
| Fayad, W; Felth, J; Fryknäs, M; Glimelius, B; Graf, W; Gullbo, J; Hassan, S; Larsson, R; Laryea, D; Linder, S; Mahteme, H; Nygren, P; Påhlman, L; Rickardson, L | 1 |
| Ellis, A; Estey, E; Kantarjian, H; Keating, M; O'Brien, S; Zwelling, L | 1 |
| Canellakis, ZN; Costin, D; Degar, B; Drygas, JC; Mani, M; Morse, L; Newcomb, EW; Potmesil, M; Rosenberg, CR; Silber, R | 1 |
| Adams, DJ; Cohen, DP; Colvin, OM; Flowers, JL; Manikumar, G; Silber, R; Wall, ME; Wani, MC | 1 |
3 trial(s) available for camptothecin and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Drug Resistance, Neoplasm; Female; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Rate | 2009 |
Topotecan in chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Cross-Linking Reagents; DNA Topoisomerases, Type I; DNA-Binding Proteins; DNA, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Topotecan; Treatment Outcome | 1995 |
Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs.
Topics: Antineoplastic Agents; B-Lymphocytes; Camptothecin; Cell Survival; Cells, Cultured; Chlorambucil; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Staging; Sensitivity and Specificity; Tumor Cells, Cultured; Vidarabine | 1994 |
3 other study(ies) available for camptothecin and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
EZN-2208 treatment suppresses chronic lymphocytic leukaemia by interfering with environmental protection and increases response to fludarabine.
Topics: Adult; Aged; Animals; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Female; Gene Expression Regulation, Leukemic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Middle Aged; Neoplasm Transplantation; Polyethylene Glycols; Treatment Outcome; Tumor Microenvironment; Vidarabine | 2020 |
Novel activity of acriflavine against colorectal cancer tumor cells.
Topics: Acriflavine; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Female; Fluorouracil; High-Throughput Screening Assays; Humans; Irinotecan; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2011 |
Pre-clinical evaluation of SN-38 and novel camptothecin analogs against human chronic B-cell lymphocytic leukemia lymphocytes.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; Drug Screening Assays, Antitumor; Humans; Irinotecan; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Nucleic Acid Synthesis Inhibitors; RNA, Neoplasm; Tumor Cells, Cultured | 1999 |